A detailed history of China Universal Asset Management Co., Ltd. transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 36,612 shares of BLUE stock, worth $13,180. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,612
Previous 22,363 63.72%
Holding current value
$13,180
Previous $21,000 9.52%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$0.47 - $1.35 $6,697 - $19,236
14,249 Added 63.72%
36,612 $19,000
Q2 2024

Jul 19, 2024

SELL
$0.85 - $1.26 $12,084 - $17,913
-14,217 Reduced 38.87%
22,363 $21,000
Q1 2024

Apr 29, 2024

BUY
$0.91 - $1.75 $21,779 - $41,882
23,933 Added 189.24%
36,580 $47,000
Q4 2023

May 21, 2024

SELL
$1.32 - $4.83 $31,591 - $115,596
-23,933 Reduced 65.43%
12,647 $17,000
Q4 2023

Jan 23, 2024

BUY
$1.32 - $4.83 $13,068 - $47,817
9,900 Added 360.39%
12,647 $17,000
Q3 2023

May 21, 2024

BUY
$3.02 - $4.05 $4,083 - $5,475
1,352 Added 96.92%
2,747 $8,000
Q3 2023

Oct 30, 2023

BUY
$3.02 - $4.05 $4,083 - $5,475
1,352 Added 96.92%
2,747 $8,000
Q1 2023

May 21, 2024

BUY
$3.14 - $8.22 $1,736 - $4,545
553 Added 65.68%
1,395 $4,000
Q1 2023

Apr 27, 2023

BUY
$3.14 - $8.22 $1,736 - $4,545
553 Added 65.68%
1,395 $4,000
Q4 2022

May 21, 2024

SELL
$5.77 - $8.49 $206,208 - $303,415
-35,738 Reduced 97.7%
842 $5,000
Q4 2022

Jan 31, 2023

BUY
$5.77 - $8.49 $692 - $1,018
120 Added 16.62%
842 $6,000
Q3 2022

Oct 21, 2022

BUY
$3.75 - $7.39 $2,707 - $5,335
722 New
722 $5,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $27.8M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.